Seizing control of KCC2: a new therapeutic target for epilepsy YE Moore, MR Kelley, NJ Brandon, TZ Deeb, SJ Moss Trends in neurosciences 40 (9), 555-571, 2017 | 146 | 2017 |
KCC2 activity is critical in limiting the onset and severity of status epilepticus L Silayeva, TZ Deeb, RM Hines, MR Kelley, MB Munoz, HHC Lee, ... Proceedings of the National Academy of Sciences 112 (11), 3523-3528, 2015 | 144 | 2015 |
Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo S Sivakumaran, RA Cardarelli, J Maguire, MR Kelley, L Silayeva, ... Journal of Neuroscience 35 (21), 8291-8296, 2015 | 116 | 2015 |
Expandable and rapidly differentiating human induced neural stem cell lines for multiple tissue engineering applications DM Cairns, K Chwalek, YE Moore, MR Kelley, RD Abbott, S Moss, ... Stem cell reports 7 (3), 557-570, 2016 | 80 | 2016 |
Locally reducing KCC2 activity in the hippocampus is sufficient to induce temporal lobe epilepsy MR Kelley, RA Cardarelli, JL Smalley, TA Ollerhead, PM Andrew, ... EBioMedicine 32, 62-71, 2018 | 59 | 2018 |
Compromising KCC2 transporter activity enhances the development of continuous seizure activity MR Kelley, TZ Deeb, NJ Brandon, J Dunlop, PA Davies, SJ Moss Neuropharmacology 108, 103-110, 2016 | 57 | 2016 |
Discovery of the migraine prevention therapeutic aimovig (Erenumab), the first FDA-approved antibody against a G-protein-coupled receptor CT King, CV Gegg, SNY Hu, H Sen Lu, BM Chan, KA Berry, DW Brankow, ... ACS Pharmacology & Translational Science 2 (6), 485-490, 2019 | 30 | 2019 |
KCC2 is required for the survival of mature neurons but not for their development G Kontou, SFJ Ng, RA Cardarelli, JH Howden, C Choi, Q Ren, ... Journal of Biological Chemistry 296, 2021 | 19 | 2021 |
The role of deficits in KCC2-mediated ion transport in the development and severity of temporal lobe epilepsy M Kelley Tufts University-Graduate School of Biomedical Sciences, 2018 | | 2018 |